(Q38131563)

29 August 2017

title

Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates (English)

1 reference

29 August 2017

1 reference

1 reference

Puja Sapra

1

1 reference

29 August 2017

Alison Betts

series ordinal

2

1 reference

29 August 2017

Joseph Boni

series ordinal

3

1 reference

29 August 2017

language of work or name

English

0 references

publication date

26 August 2013

1 reference

Expert Review of Clinical Pharmacology

29 August 2017

published in

1 reference

29 August 2017

volume

6

1 reference

29 August 2017

issue

5

1 reference

29 August 2017

page(s)

541-555

1 reference

Monoclonal antibody-based therapies in cancer: advances and challenges

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

General pharmacokinetic model for drugs exhibiting target-mediated drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Model of chemotherapy-induced myelosuppression with parameter consistency across drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Peripheral neuropathy induced by microtubule-stabilizing agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Trial watch: Phase II failures: 2008-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

PK/PD modelling and simulations: utility in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Quantitative disease, drug, and trial models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2013.827405

10.1586/17512433.2013.827405

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference